The demand for intraocular lenses (IOLs) pre-loaded in single-use sterile injectors is a logical step in the evolution of cataract surgery.
Prepak in terms of visual acuity improvement, and then to determine any potential adverse effects peri-and post-operatively. Overall therapeutic efficacy was also evaluated (assessment by investigator).
The study was conducted between May 2004 (first inclusion) and June

(latest results
. The study protocol was based on ISO 13503-7, including three reports (pre-, peri-and post-operative at 2±1 months).
Ten investigators were selected, each treating 30 patients suffering from senile cataracts. Three hundred and one patients were treated (one investigator treated 31 patients).
The inclusion criteria were age greater than 50 years (both sexes) and scheduled extraction of the crystalline lens by phacoemulsification followed by implantation in the capsular bag of a GENIUM AFI 5.5 Prepak pre-loaded IOL. The exclusion criteria were traumatic cataract, uveitis, keratitis or other inflammation of the anterior segment, uncontrolled glaucoma and any retinopathy that would prevent satisfactory visual acuity being obtained.
The patient group ranged from 46 to 99 years of age (mean age 75.2±8.1 years) and 64% were women. Age distribution is shown in Figure 2 . Very few deviations to the protocol were accepted: three patients with early senile cataracts and 13 patients with posterior segment diseases who achieved visual improvement were included. The GENIUM AFI 5.5 Prepak was implanted in all patients. The whole range of powers (+14.0 to +26.0D) available at the time of the study were used. Figure 3 .
Distribution of these powers is shown in
Device Description
GENIUM AFI 5.5 Prepak is a foldable acrylic hydrophilic IOL pre-loaded in a single-use injector. The whole system is delivered sterile, double-packed in a sealed glass vial containing a solution. Sterility is obtained by steam autoclaving. The GENIUM injector and the amniotic fluid index (AFI) IOL have been specifically designed together for an easy and reproducible injection. The GENIUM injector and IOL have several unique features:
• The GENIUM injector is simple, being made from two major components -syringe and piston -and extremely compact.
• The syringe, or 'injector cartridge', containing the unfolded IOL is made of transparent polypropylene, allowing full visual control at any stage of folding and injection. The bevelled and flattened tip is designed to go through a 3.2mm incision without enlarging it.
• The patented 'folding piston' has two exclusive flexible pushing rods to maintain the IOL in perfect alignment during folding and injection.
As it is made of polyetherimide it is strong, stable and heat-resistant, and its natural amber colour contributes to the ease of visual control.
• No separate IOL container is used and no mechanism is required to compress the IOL prior to pushing the piston.
• The lubricating viscoelastic solution (ophthalmic viscosurgical device
[OVD]) can be easily introduced from the injector tip using a standard cannula.
• A bimanual technique is recommended when handling the GENIUM injector as it offers better control. Also, a retraction of the piston is required to release the IOL; this allows the IOL to be directly injected in a horizontal position and placed directly in the capsular bag, without needing to use another instrument.
• The patented AFI tripod IOL is specifically designed to fit the GENIUM injector. The two superior haptics in contact with the rods keep the IOL aligned until the optic is folded; the narrow single inferior haptic can precede the optic during injection.
• The AFI tripod IOL is easy to place and to centre, offering great stability inside the capsular bag.
Results
Peri-operative Results
Peri-operative results are shown in Table 1 .
Post-operative Results
Quantitative results comparing pre-and post-operative outcomes are shown in Table 2 . Keratometry changes were also analysed: 85% of corneas remained unchanged at ±0.25D, indicating that 3.2mm incisions with the GENIUM AFI 5.5 Prepak do not induce astigmatism.
Visual acuity (VA) recovers well with the GENIUM AFI 5.5 (see Figure 4 ). (sphere). Therefore, the A-constant is obviously oversized at 118.3D.
As calculations performed by investigators are ignored, a statistical approach was made using the SRK II formula. The A-constant, re-calculated from SRK II, shows a relatively wide distribution (see Figure   5 ). However, this distribution is narrower for several individual 
Adverse Events
There were only four adverse events during surgery: one case each of capsule rupture, capsule micro-rupture, zonula de-insertion and torn IOL (immediately replaced by an identical IOL at the same power).
Other observations during surgery were: two cases of the IOL being trapped in the injector; two cases where there was difficulty with release/unfolding of the haptics; two cases where the IOL was considered 'mobile' on day zero (both became stable later); one case of mild deformation of the pupil; and five cases of punctual white deposits on the surface of the lens. These deposits are reported to stick strongly to the IOL and are therefore difficult to remove by aspiration. However, they neither affect patient vision nor induce reaction and they have all disappeared spontaneously within three months following surgery.
E U R O P E A N O P H T H A L M I C R E V I E W
Clinical Evaluation of the GENIUM AFI 5.5 Prepak in Cataract Surgery Figure 5 ) Intraocular 14.9 (2.6) 14.5 (2.2) Unchanged pressure (mmHg) from 10 to 24 from 8 to 27 (see Figure 6 ) 
Quantitative results are given as mean (with standard deviation [SD] inside parentheses). *Visual acuity non-measurable (patient just counted fingers). **Target for post-operative refraction (emmetropia considered when data not documented). ***Estimated A-constant initially proposed by LCA; it was later modified to 118.0 (ultrasound biometry).
Assessment by Investigator
The results of the assessment of overall therapeutic efficacy by the investigator are shown in Table 3 .
Discussion
The clinical results obtained with the GENIUM AFI 5. 
Evolution of the GENIUM AFI Prepak
Since the initial introduction of the Genium AFI Prepak onto the market 
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LG1 • Waiting times differed significantly between the countries analysed, and is greatly influenced by total expenditure on health,
but not by other country-specific health indicators.
• Switzerland achieved the shortest waiting times (mean 1.3 months, SD 0.9). The two longest waiting times were found in Spain (mean 6.2 months, SD 6.4) and Sweden (mean 5.8 months, SD 7.2).
• The short waiting times in Switzerland and France were attributable to the high number of cataract surgeons, whereas Sweden suffers a paucity of surgeons.
• In Sweden, Italy and Switzerland, complicated cases are prioritised as more urgent than in The Netherlands, France, Germany and Spain, where complicated cases require access to beds in hospitals, which can result in delays.
Health Expenditure Determines Cataract Surgery Waiting Times
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